ReviewClinical and experimental otorhinolaryngology2026
Nrf2: A Promising Therapeutic Target for Glucocorticoid-Resistant Chronic Rhinosinusitis.
Review in Clinical and experimental otorhinolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zebrafish as a multimodal platforms for anti-inflammatory phytomedicine discovery and translation.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis (CRS) presents a challenge for otolaryngologists due to its complex management and high recurrence rates. Glucocorticoids (GCs) are widely employed for their potent anti-inflammatory effects across various inflammatory conditions and play a pivotal role in treating CRS. However, some patients exhibit insensitivity to GC therapy, resulting in GC resistance (GCR). Oxidative stress is a key factor contributing to GCR development, whereas the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway functions as a vital cellular defense mechanism against oxidative stress-induced damage. Investigating the Nrf2 signaling pathway holds promise for advancing our understanding of GC sensitivity and refining its therapeutic application in CRS. This article reviews the relationship between GC sensitivity and the Nrf2 signaling pathway, as well as potential Nrf2-related drugs. Studies show that Nrf2 activators-when used alone or in combination with GCs-more effectively inhibit the release of inflammatory factors and mitigate oxidative stress damage than GC monotherapy, marking them as a promising target for CRS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.